Clinical significance of urotensin 2 plasma level in patients diagnosed with prostate cancer.

• DOI: 10.1200/jco.2025.43.5_suppl.249
• Publication Date: 2025-02-18T14:43:07Z
• Authors: Cigdem Dinckal; Zeynep Gulsum Guc; Huriye Erbak Yilmaz; Mustafa Dinckal; Semiha Ozgul; Gamze Ozkan; Sinan Unal; Yasar Yildiz; Utku Oflazoglu; Tarik Salman; Ahmet Alacacioglu; Yuksel Kucukzeybek
• Keywords: Urotensin II; Clinical Significance

249 Background: Urotensin-II is a small somatostatin-like cyclic peptide characterized by its potent vasoconstrictor activity. (UT-II) and receptor (UTR) have been shown to play role in the formation of different epithelial cancers. To date, many studies reported prostate cancer that provide genetic contributions with diagnostic, prognostic therapeutic potential for carcinogenesis. However, urotensin-II carcinogenesis has not yet elucidated. There are several limitations using PSA as biomarker follow-up. More accurate specific biomarkers needed improve diagnosis monitoring cancer. Our study aimed reveal clinical importance plasma UT-2 level metastatic patients investigate correlation parameters such pathological Gleason Score. Methods: Patients who applied İzmir Katip Celebi University Atatürk Training Research Hospital Medical Oncology Polyclinic 2023 were included our study. The demographic information was scanned from oncology file system recorded. Measurements ÜT-2 made biochemistry specialist at Biochemistry Laboratory. For ELISA method, Urotensin 2 (Elabscience lot no: E-EL-2047) kit used Biotek (ELx800, USA) semi-automatic device. Results: A total 147 patients, 100 47 control groups, No statistically significant difference observed between groups terms additional diseases may be related level: Diabetes Mellitus, hypertension, peripheral artery disease, coronary chronic renal failure smoking characteristics (p>0.05). When PT-2 compared de-novo non-de-novo metastasis both had higher average than (p = 0.004). cut-off value determined 1.269 ng/mL. sensitivity, specificity, positive predictive negative found 81%, 53%, 79% 57%, respectively. Conclusions: Today, continuing rapidly increase efficiency find new tumor markers. In study, levels other groups. This first literature cancer, an important predicting prognosis